Wenxi Zhang

Wenxi Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
YLYuchen Liu
Yuchen Liu
XZXin Zong
Xin Zong
CWCao Wenye
Cao Wenye
WZWenxi Zhang
Wenxi Zhang
NZNingzhi Zhang
Ningzhi Zhang
NYNing Yang
Ning Yang
Retinitis pigmentosa (RP) poses a significant threat to eye health worldwide, with prevalence rates of 1 in 5000 worldwide. This genetically diverse retinopathy is characterized by the loss of photoreceptor cells and atrophy of the retinal pigment epithelium. Despite the involvement of more than 3000 mutations across approximately 90 genes in its onset, finding an effective treatment has been challenging for a considerable time. However, advancements in scientific research, especially in gene therapy, are significantly expanding treatment options for this most prevalent inherited eye disease, with the discovery of new compounds, gene-editing techniques, and gene loci offering hope for more effective treatments. Gene therapy, a promising technology, utilizes viral or non-viral vectors to correct genetic defects by either replacing or silencing disease-causing genes, potentially leading to complete recovery. In this review, we primarily focus on the latest applications of gene editing research in RP. We delve into the most prevalent genes associated with RP and discuss advancements in genome-editing strategies currently employed to correct various disease-causing mutations.

15 June 2023 in BMC Genomics
Verified
Journal Article
Open access
PDF file
NYNing Yang
Ning Yang
NZNingzhi Zhang
Ningzhi Zhang
ZWZhiyi Wang
Zhiyi Wang
CWCao Wenye
Cao Wenye
XHXuejun He
Xuejun He
YXYiqiao Xing
Yiqiao Xing
Background: Retinal neovascularization (RNV) is a leading cause of blindness worldwide. Long non-coding RNA (lncRNA) and competing endogenous RNA (ceRNA) regulatory networks play vital roles in angiogenesis. The RNA-binding protein galectin-1 (Gal-1) participates in pathological RNV in oxygen-induced retinopathy mouse models. However, the molecular associations between Gal-1 and lncRNAs remain unclear. Herein, we aimed to explore the potential mechanism of action of Gal-1 as an RNA-binding protein. Results: A comprehensive network of Gal-1, ceRNAs, and neovascularization-related genes was constructed based on transcriptome chip data and bioinformatics analysis of human retinal microvascular endothelial cells (HRMECs). We also conducted functional enrichment and pathway enrichment analyses. Fourteen lncRNAs, twenty-nine miRNAs, and eleven differentially expressed angiogenic genes were included in the Gal-1/ceRNA network. Additionally, the expression of six lncRNAs and eleven differentially expressed angiogenic genes were validated by qPCR in HRMECs with or without siLGALS1. Several hub genes, such as NRIR, ZFPM2-AS1, LINC0121, apelin, claudin-5, and C-X-C motif chemokine ligand 10, were found to potentially interact with Gal-1 via the ceRNA axis. Furthermore, Gal-1 may be involved in regulating biological processes related to chemotaxis, chemokine-mediated signaling, the immune response, and the inflammatory response. Conclusions: The Gal-1/ceRNA axis identified in this study may play a vital role in RNV. This study provides a foundation for the continued exploration of therapeutic targets and biomarkers associated with RNV.

8 October 2025 in Experimental Eye Research
Verified
Journal Article
Closed access
XHXuejun He
Xuejun He
NYNing Yang
Ning Yang
NZNingzhi Zhang
Ningzhi Zhang
WCWenye Cao
Wenye Cao
LYLu Yu
Lu Yu
YXYiqiao Xing
Yiqiao Xing

27 May 2026 in Experimental Eye Research
Verified
Journal Article
Closed access
PLPei Lin
Pei Lin
NZNingzhi Zhang
Ningzhi Zhang
WZWenxi Zhang
Wenxi Zhang
YXYiqiao Xing
Yiqiao Xing
NYNing Yang
Ning Yang